CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

ProTom International

Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.

Foamix

Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.

Unisource NTC

Unisource NTC is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unicep Packaging

Unicep Packaging is a Sandpoint, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Circassia

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies.